105 BLA 125742 0 08 20 2021 Telecon Advice Information

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

3

Document text

From:  Naik, Ramachandra  
Sent:  Friday, August 20, 2021 2:08 PM  
To: Boyce, Donna < [email protected] > 
Cc: Malarkey, Mary < [email protected] >;  Gruber, Marion < [email protected] >; 
Harkins Tull, Elisa < [email protected] >;  Rohlfing, Paul < [email protected] >; Aghajani 
Memar, Neda <[email protected] >; Smith, Michael (CBER) 
<[email protected] >;  Gottschalk, Laura < [email protected] > 
Subject:  RE: Lot Numbers for the COVID Launch Lots [BLA STN 125742/0 - COMIRNATY]  
 
De
ar Donna,  
 
Thank you for the information!  
 
Please note that we do not consider these EUA -labeled “lots in the field” to comply with the BLA at this 
time since lot release activities have yet to be agreed upon and performed.   We will work with you to 
develop a lot re lease approach after the initial BLA approval occurs.  Please ensure that these “lots in 
the field” are not listed in the cvdvaccine -us.com/resources website included in the Dear HCP Letter 
(submitted in draft as amendment 64 to the BLA on August 19, 2021) .  We will provide comments on the 
Dear HCP Letter in a separate communication.  
 
Please confirm receipt of this message and let me know if you have any questions or need additional 
information.  
Regards,  
Ram  
 
Ramachandra S. Naik, Ph.D.  
Biologist (Regulatory ) / Primary Reviewer           
Center for Biologics Evaluation and Research  
Office of Vaccines Research and Review  
U.S. Food and Drug Administration  
Tel: 301- 796-2640 
ramachandra.naik @fda.hhs.gov   
 
 
         
 
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FRO M DISCLOSURE 
UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e -mail or phone.  
 
 
 From:  Boyce, Donna < [email protected] >  
Sent:  Thursday, August 19, 2021 6:49 PM  
To: Malarkey, Mary < [email protected] >; Naik, Ramachandra 
FDA-CBER-2021-5683-1150333
<[email protected] >; Gruber, Marion < [email protected] > 
Cc: Harkins Tull, Elisa < [email protected] >; R ohlfing, Paul < [email protected] >; 
Aghajani Memar, Neda < [email protected] > 
Subject:  RE: [EXTERNAL] Lot Numbers for the COVID Launch Lots  
 
CAUTION:  This email originated from outside of the organization. Do no t click links or open attachments unless you 
recognize the sender and know the content is safe.  
 
Dear All,  
Attached please find the list of lots in the field that comply with the BLA. We do not have visibility to the consumption/inventory of these lots so cannot say how many doses per lots remain.  
 Also, we have not shipped any doses from the 7 “launch lots.” These are planned for shipment in Sept. Therefore, the  million dose remain in our control.  
 Please contact m e with any questions.  
Kind regards,  
Donna  
 From:  Malarkey, Mary <[email protected] >  
Sent:  Thursday, August 19, 2021 5:37 PM  
To: Boyce, Donna < Donna.Boyc e@p f izer.com >; Naik, Ramachandra < [email protected] >; 
Gruber, Marion < [email protected] > 
Cc: Harkins Tull, Elisa < [email protected] >; R ohlfing, Paul < [email protected] >; 
Aghajani Memar, Neda < [email protected] > 
Subject:  RE: [EXTERNAL] Lot Numbers for the COVID Launch Lots  
 Dea
r Donna  
 
Thanks so much for this!  I think we have these lots in house now.   I probably wasn’t clear to Peter that 
we were still waiting to get the other lots in the field that would be considered BLA compliant.   It 
would   be very helpful to get a list of those and some idea of magnitude.    I presume the seven lots have 
diminished from the  million doses at this point.  
 We will also have comments on the Dear HCP.     
 
Thanks again  
 Mary  
 From:  Boyce, Donna < [email protected] >  
Sent:  Thursday, August 19, 2021 5:33 PM  
To: Naik, Ramachandra < [email protected] > 
Cc: Malarkey, Mary < [email protected] >; H arkins Tull, Elisa < [email protected] >; 
Rohlfing, Paul < [email protected] >; A ghajani Memar, Neda < [email protected] > 
Subject:  [EXTERNAL] Lot Numbers for the COVID Launch Lots  
 
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150334
CAUTION:  This email originated from outside of the organization. Do not click links or open attachments unless you 
recognize the sender and know the content is safe.  
 
Dear Ram,  
I understand from Peter Marks that the CBER review team is looking for the lot numbers of the launch lots.  
These are the seven Lot Numbers:  
 
1. FD7220 
2. FE3592 
3. FF2587 
4. FF2588 
5. FF2590 
6. FF2593 
7. FF8841 
 
Please contact me with any questions.  
Kind regards  
Donna  
 
FDA-CBER-2021-5683-1150335